Information for providers

Do you have a patient who cannot afford treatment for a STD such as syphilis, gonorrhea or chlamydia?

If a patient has barriers that keeps them from getting treatment, the Department of Health will provide treatment (ex. Rocephin). If you refer the patient, we will schedule an appointment. However, walk-in patients without an appointment will not be turned away.

Questions or to refer a patient please call DOH-Volusia at 386-281-6645.

Having trouble contacting a patient with a test result? We can help!

Your Department of Health is here to help to educate and reduce the number of STDs in Florida. Early notification is key to reducing infection.

When trying to notify a patient, physicians often tell us they have experienced:

• A disconnected telephone number

• Returned mailings

• Patient not picking-up the prescribed medication.

• Parents intercepting their child's telephone call and getting upset with the provider for not disclosing the reason for the call.

• Spouses not being cooperative and demanding the reason for the telephone call.

Department of Health staff can help to locate patients and refer them back to your office. We also will call your office after the patient is located.

Questions? Please call DOH-Volusia at 386-281-6645.

A patient with two or more STDs infections in the last six months?

Department of Health staff can provide:

• Additional counseling on STDs, mode of transmission, risk reduction counseling.

• Education on different types and brands of protective barriers.

• Effective coaching on encouraging the sex partner to be tested and treated.

Questions? Please call DOH-Volusia at 386-281-6645.

Physician Resources:

• Download a printable version of the CDC STD treatment wall chart.

• Download a viewable version of the CDC's 2015 Summary of CDC Treatment Guidelines.

More information on the CDC Sexually Transmitted Diseases Treatment Guidelines and resources are online here.

CDC Releases Updated Gonorrhea Treatment Recommendations

CDC has updated its recommendation for the treatment of uncomplicated gonorrhea in adults. Gonorrhea should now be treated with just one higher dose (500 mg) injection of ceftriaxone, and dual therapy is no longer the recommended approach. The new recommendations, briefly summarized below, are available in 2020 Update to CDC's Treatment for Gonococcal Infections, a special policy note published on December 17 in MMWR, and this new recommendation supersedes the gonorrhea treatment recommendation included in the 2015 STD Treatment Recommendations.

1. Treat gonorrhea infections with a single 500 mg injection of ceftriaxone.
2. A test-of-cure is not needed for people who receive a diagnosis of uncomplicated urogenital or rectal gonorrhea unless symptoms persist.
3. A test-of-cure is recommended in people with pharyngeal gonorrhea 7-14 days after the initial treatment, regardless of the regimen.
4. Patients who have been treated for gonorrhea should be retested three months after treatment to ensure there is no reinfection.
5. As always, facilitate partner testing and treatment.

Drug-resistant gonorrhea remains an urgent public health threat; in fact, half of all gonorrhea infections are resistant to at least one antibiotic.

The change from dual therapy to monotherapy was prompted by three items:

1. Antimicrobial stewardship and the need to minimize antibiotic exposure unless the benefit clearly outweighs the risk, an important consideration for all infections and not just STIs
2. Further evidence and understanding of ceftriaxone's pharmacokinetics (how drugs move in the body) and pharmacodynamics (biochemical and physiologic effects of drugs) in relation to identifying the optimal dose to treat gonorrhea; and,
3. Signs that azithromycin resistance is increasing.

While CDC is not seeing treatment failures in the U.S. yet, continuing to monitor and prepare for resistance is paramount. It's important that researchers and pharmaceutical companies jump-start research to identify or develop novel, effective treatment options.

Effective treatment - the cornerstone of U.S. gonorrhea control efforts - begins with action from state and local health departments, health care providers, community-based organizations, and other partners in the field of STDs. By implementing this new gonorrhea treatment recommendation now, along with scaling up prevention education and counseling, we can prevent this common infection with potentially severe health consequences.

Of note, CDC expects to publish the revised STI Treatment Guidelines in 2021, and we look forward to sharing those updates with you. Please remember that the National Network of STD Clinical Prevention Training Centers (NNPTC) is your resource for the prevention and clinical management of STDs. To view the national training calendar, register for courses, find resources, and access the STD Clinical Consultation Network, visit the NNPTC at www.nnptc.org.